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COriginal articleC-reactive protein but not atrial dysfunction predicts
recurrences of atrial fibrillation after cardioversion in patients
with preserved left ventricular function
Federico Lombardia, Fabrizio Tundoa, Sebastiano Bellettia, Antonio Manteroa
and Gian Vico Melzi d’ErilbObjectives Maintenance of sinus rhythm after
cardioversion of atrial fibrillation is amajor clinical challenge
also in patients with preserved left ventricular function.
Subclinical inflammation and atrial strain have been
recognized as important contributors to atrial fibrillation
onset and perpetuation. Aim of the study was to compare
the predictive role of C-reactive protein (CRP) and indices of
atrial dysfunction in relation to subacute arrhythmic
recurrence rate in patients with persistent atrial fibrillation
and normal left ventricular ejection fraction (LVEF).
Methods We studied 53 patients with a mean LVEF of
58.7W6%. Left atrial diameter and area, left atrial auricle
emptying velocity, N-terminal pro-b-type natriuretic peptide
(NT-proBNP) and CRP levels were determined few hours
before electrical cardioversion. NT-proBNP and CRP levels
were also measured 1h and 3 weeks after cardioversion.
Results Subacute atrial fibrillation recurrences were
documented in 18 (33.9%) patients. Whereas none of the
parameters reflecting atrial dysfunction predicted
arrhythmic outcome, higher CRP levels (>3.0mg/l) were
significantly associated with atrial fibrillation recurrences
[odds ratio (OR): 1.6; 95% confidence interval (CI): 1.4–2.5;
PU0.031]. No changes in CRP levels were evident after
cardioversion independently of underlying rhythm. On theopyright © Italian Federation of Cardiology. Unau
1558-2027  2008 Italian Federation of Cardiologycontrary, NT-proBNP levels, which were correlated with left
atrial auricle emptying velocity, significantly decreased only
in patients whomaintained sinus rhythm (from 638W329 to
295W261pg/ml; P<0.001).
Conclusion The present study demonstrates that in
patients with persistent atrial fibrillation and preserved
LVEF, CRP level is an independent predictor of atrial
fibrillation subacute recurrence rate, whereas none of the
indices of atrial dysfunction is associated with arrhythmic
outcome. NT-proBNP levels reflect, instead, the
hemodynamic alterations secondary to arrhythmia
presence. J Cardiovasc Med 9:581–588 Q 2008 Italian
Federation of Cardiology.
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Maintenance of sinus rhythm after cardioversion of atrial
fibrillation is a major clinical challenge. It is a common
experience that more than one-third of patients under-
going cardioversion present early recurrences despite
appropriate antiarrhythmic therapy [1–3]. Thereafter,
the incidence of recurrences substantially and progres-
sively decreases. Identification of factors favoring atrial
fibrillation recurrence, through a better comprehension of
arrhythmia pathophysiology [4,5], could suggest new
strategies aimed to improve our success in maintaining
sinus rhythm.
In the past, classical factors known to influence atrial
fibrillation history were the presence of left ventricular
dysfunction, left atrial enlargement, arrhythmia durationand history of hypertension [1]. More recently, other
factors have been found to play a major role in atrial fib-
rillation onset and perpetuation. Among them, subclinical
inflammation [6,7] and atrial strain [5] seem to be themost
important ones. Indeed, several reports have indicated that
inflammation is not the only central contributor to ather-
othrombosis but also there is a mechanistic link between
inflammatory processes and development of atrial fibrilla-
tion [6]. Moreover, strain-mediated changes in atrial
volume and function have been identified as critical com-
ponents of atrial structural remodeling [5].
The aim of this study was to compare the predictive role
of indices of atrial dysfunction including left atrial
diameter (LAD), left atrial area (LAA), left atrial auricle
emptying velocity (LAAEV), N-terminal pro-b-typethorized reproduction of this article is prohibited.
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Table 1 Demographic and clinical characteristics at baseline evaluation (T-0) for all patients as a whole and in relation to AF recurrence
during 3-week follow-up (T-3W)
All population (n¼53) AF recurrences (n¼18) SR maintenance (n¼35) P value
Age (years) 677 656.6 67.86.9 NS
Sex (M/F) 37/16 12/6 25/10 NS
LVEF (%) 58.75.8 596.2 58.55.6 NS
LA enlargement (%) 39 (71.7%) 12 (66.6%) 27 (77.1%) NS
LA area (mm2) 242.6 23.63.2 24.32.4 NS
LAA emptying velocity (cm/s) 30 (20–30) 30 (20–30) 30 (20–30) NS
History of hypertension (%) 33 (62.2%) 10 (55.5%) 23 (65.7%) NS
Diabetes (%) 3 (5.6%) 1 (5.5%) 2 (5.7%) NS
History of AF (%) 23 (43.4%) 8 (44.45) 15 (42.8%) NS
History of smoking (%) 15 (28.3%) 7 (38.8%) 8 (22.8%) NS
Warfarin (%) 53 (100%) 18 (100%) 35 (100%) NS
Beta-blockers (%) 17 (32%) 6 (33.3%) 11 (31.4%) NS
ACEI/ARBs (%) 33 (62.2%) 11 (61.1%) 22 (62.8%) NS
AA-1C (%) 3 (5.6%) 1 (5.5%) 2 (5.7%) NS
Digoxin (%) 4 (7.5%) 2 (11.1%) 2 (5.7%) NS
Amiodarone (%) 29 (54.7%) 9 (50%) 20 (57.1%) NS
CRP (mg/l) 2.4 (0.91–3.70) 3.70 (2.2–5.9) 1.96 (0.6–3.0) P¼0.014
NT-proBNP values (pg/ml) 664465 735370 638329 NS
CRP data are presented as median interquartile range (IQR). AA-1C, class 1C antiarrhythmic drugs; ACEI/ARBs, angiotensin conversion enzyme inhibitors/angiotensin
receptor blockers; AF, atrial fibrillation; LVEF, left ventricle ejection fraction; LA, left atrium; LAA, left atrium appendage; NT-proBNP, N-terminal pro-b-type natriuretic
peptide; SR, sinus rhythm; T-0, baseline evaluation; T-3W, 3-week evaluation.
Table 2 Study protocol design
T-0
(n¼53)
T-1h
(n¼53)
T-1W
(n¼53)
T-2W
(n¼53)
T-3W
(n¼53)
History collection 
Physical examination  
ECG   
TTE 
TEE 
Phone contact  
Blood sample collection  a 
CV, cardioversion; T-0, baseline evaluation before CV; T-1 h, evaluation 1 h after
CV; T-1W, T-2W, T-3W, evaluation, respectively, 1, 2 and 3 weeks after CV; TTE,
transthoracic echocardiography; TEE, transesophageal echocardiography.
a Blood sample collection at T-1h was performed just for 19 subjects.natriuretic peptide (NT-proBNP) levels and of subclini-
cal inflammation (CRP) on subacute atrial fibrillation
recurrences in hypertensive patients with persistent atrial
fibrillation and preserved left ventricular ejection fraction
(LVEF).
Methods
Study population
From our outpatient arrhythmia clinic, we prospectively
enrolled 53 consecutive patients with persistent atrial
fibrillation, preserved ventricular function (defined as a
LVEF> 45%), indication and consent for electrical
cardioversion. A diagnosis of stage 1 hypertension or
high normal blood pressure was present in, respectively,
62 and 21% of cases, lone atrial fibrillation in 14% of
subjects. Patients with ischemic or valvular cardiomyo-
pathy, NYHA functional classes II–IV, signs of acute
or chronic inflammatory disease, malignancies, sign-
ificant renal or hepatic failure, valvular cardiomyopathy,
left ventricular hypertrophy and thyrotoxicosis were
excluded from a possible inclusion in this study. The
cut-off value of LVEF greater than 45% (measured
during ongoing arrhythmia) was selected to include most
of the patients without organic cardiomyopathy and heart
failure symptoms. It is worth noting that of the six
patients with ejection fraction of less than 55%, only
two had ejection fraction below 50%.
All patients were on anticoagulant therapy with warfarin
targeting an INR range 2–3. The clinical characteristics
and concomitantmedical therapy are described inTable 1.
The study protocol was approved by our Institutional
Ethical Committee. Every patient signed a written
informed consent.yright © Italian Federation of Cardiology. UnauthStudy design
Before electrical cardioversion (baseline evaluation time:
T-0; Table 2), every patient underwent physical exam-
ination, transthoracic (TTE) and transesophageal (TEE)
echocardiographic evaluation to determine LAD, LAA,
LAAEV and LVEF. TTE was performed within 2 weeks
before cardioversion, whereas TEE on the same morning
of the procedure. Blood samples for NT-proBNP and
high-sensitivity CRP measurements were collected
immediately before and 1 h after cardioversion as well
as at 3-week follow-up. NT-proBNP levels were deter-
mined by an electrochemiluminescence immunoassay
on an Elecsys analyzer (Roche Diagnostics, Mannheim,
Germany). Normal cut-off values were less than
264 pg/ml in men and less than 337 pg/ml in women.
The analytical range extended from 5 to 35 000 pg/ml.
Intraassay (interassay) % coefficient of variation was 3.5%
(4.1%) and 2.9% (3.7%) at concentrations of 251 and
805 pg/ml, respectively. High-sensitivity CRP levels
were determined by immunonephelometric assay using
BN II System (Dade Behring, Marburg, Germany).
Normal cut-off value was less than 3mg/l. The detectionorized reproduction of this article is prohibited.
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variation was 3.2% (3.8%) and 2.5% (3.5%) at concen-
trations of 0.5 and 26mg/l, respectively.
LVEF was calculated with Simpson method. The left
atrial enlargement was defined as a diameter of greater
than 40mmmeasured inM-mode in long-axis parasternal
view or as LAA of greater than 20 cm2 measured in
four-chamber apical view as described in the American
Society of Echocardiography guidelines [8]. LAAEV was
measured by Pulse Wave Doppler analysis during trans-
esophageal examinations. Values less than 25 cm/s were
considered abnormal [9].
Electrical cardioversion was performed in fasting state
during deep sedation with intravenous propofol
(1–2mg/kg). Bifasic DC shock (LifePak 12 defibrillator;
Medtronic Inc., Minneapolis, USA) was delivered with
rising energies when needed, starting from 100 J (single
shock in almost all cases). In a subgroup of patients (n¼ 19;
35.8%), a second blood sample was collected 1h after
cardioversion and sinus rhythm recovery to evaluate the
possible effects of cardioversion on NT-proBNP levels
(T-1h).
Patients’ follow-up was planned with weekly phone
contacts to investigate patient’s symptoms in the first
2 weeks after cardioversion (time: T-1W; T-2W) and an
ambulatory visit with ECG recording, 3 weeks after
cardioversion (T-3W). Recurrences within this time
frame were considered as subacute recurrences. During
the medical control, blood samples were collected for the
final CRP and NT-proBNP determination. All patients
were also advised to contact our outpatient clinic when
experiencing palpitations or shortness of breath during
the 3-week follow-up period.
Statistical analysis
Data are presented as meanSD or median and inter-
quartile range (IQR) when asymmetrical distribution was
observed. Normality was assessed with Kolmogorov–
Smirnov test. Continuous variables were compared with
unpaired or paired Student’s t-test as needed (for normally
distributed values) and Mann–Whitney or Wilcoxon rank
sum test. Categorical variableswere comparedwithx2-test
or Fisher’s exact test. Correlation between variables was
calculated with Pearson’s and Spearmann’s coefficients.
Variables associated with atrial fibrillation recurrences
were investigated with logistic regression analysis. OR is
reported with 95%CI. To achieve discrimination ability of
CRP values to predict atrial fibrillation recurrences, a
receiver operating characteristics (ROC) curvewas plotted
and the optimal cut-off value for CPR in minimizing the
total number of false results and the area under the
curve were calculated. A two-sided P value of 0.05 was
considered significant. All analyses were performed with
software SPSS (Release 13.0, SPSS Inc., Chicago, USA).opyright © Italian Federation of Cardiology. UnauResults
The mean age of patients was 67 7 years, 69.8% were
men. Left atriumenlargement enlargementwas present in
39 (72%) patients. Mean LVEF and LAA area were,
respectively, 58.7 6% and 24 2.6 cm2. LAAEV was
30 cm/s (median value; IQR: 20–30 cm/s). Arrhythmia
duration ranged from 1 month to 1 year (median duration:
3 months). In 43% of the patients, a previous episode of
atrial fibrillation was managed with electrical cardiover-
sion.
In all patients sinus rhythm was successfully restored by
electrical cardioversion. As expected, this maneuver was
accompanied by a significant prolongation of mean RR
interval (from 684 146 to 946 138ms; P< 0.01). No
adverse events were associated with the procedure.
During a 3-week follow-up, 18 patients (33.9%) showed
atrial fibrillation recurrences. In most instances, no symp-
toms were reported. In two cases, in which symptoms
before the programmed ambulatory visit were reported,
an early atrial fibrillation recurrence was documented.
No significant differences were detectable between the
two groups of patients in relation to mean age, sex, anti-
arrhythmic medication or other clinical data (Table 1).
Atrial fibrillation recurrences in relation to atrial
dysfunction
At baseline evaluation (Table 1), none of the parameters
reflecting atrial enlargement or dysfunction predicted
atrial fibrillation recurrences. LAD, LAA, LAAEV
measurements were similar in patients who maintained
sinus rhythm and in patients with subacute arrhythmia
recurrences.
NT-proBNPmeanvalues (664 465pg/ml) before cardio-
version (T-0) were well above the reference normal values
of our laboratory (see Methods). Of notice was the finding
that abnormally elevated values were observed in all
patients but two, in spite of preserved LVEF and absence
of any echocardiographic evidence of left ventricular
hypertrophy. When NT-proBNP levels were analyzed
in relation to atrial fibrillation recurrences, no significant
differences were observed in patients with subacute
atrial fibrillation recurrences (735 370pg/ml) in compari-
son with those who maintained sinus rhythm (638
329pg/ml). On the contrary, persistence of sinus rhythm
was associated with a significant reduction of NT-proBNP
(from638 329 to 295 261pg/ml;P< 0.001), whereas no
decrease inpeptide concentrationwas observed inpatients
with subacute arrhythmia recurrences (from 735 370 to
757 421pg/ml; P¼ 0.86, see Fig. 1). We also observed
that the cardioversion procedure and recovery of sinus
rhythm determined a small but significant reduction
(from 691 355 to 618 311pg/ml; P¼ 0.009; Fig. 2) in
NT-proBNP levels detectable within 1h from the inter-
vention (T-1h).thorized reproduction of this article is prohibited.
Copyright © Italian Federation of Cardiology. Unauth
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N-terminal pro-b-type natriuretic peptide (NT-proBNP) values before
and 3 weeks after electrical cardioversion (CV) in patients with sinus
rhythm (SR) maintenance and atrial fibrillation (AF) recurrence. Data are
presented as meanSD.
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N-terminal pro-b-type natriuretic peptide (NT-proBNP) values before
and 1 h after successful electrical cardioversion and restoration of sinus
rhythm (19 patients). Data are presented as meanSD.
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Correlation between N-terminal pro-b-type natriuretic peptide
(NT-proBNP) values before electrical cardioversion (CV) and left atrial
appendage (LAA) emptying velocity assessed at transesophageal
echocardiography (TEE) during atrial fibrillation (r¼0.54; P<0.001).NT-proBNP levels were correlated with age (r¼ 0.3,
P¼ 0.04) and with LAAEV (r¼0.54, P< 0.001,
Fig. 3). This correlation was even more evident when
correcting NT-proBNP values for age (r¼0.58,
P< 0.001). No correlation was detectable between
NT-proBNP levels and atrial fibrillation duration.
C-reactive protein values and effects of cardioversion
Median CRP level before cardioversion was 2.4 (IQR:
0.91–3.70). When CRP levels were analyzed in relation
to arrhythmic outcome, higher values were observed
in patients with subacute arrhythmia recurrences
(3.70mg/dl, IQR: 2.2–5.9) than in those who maintained
sinus rhythm (1.96mg/dl, IQR: 0.6–3.0; P¼ 0.014,
Fig. 4). Of interest was the finding that patients in the
highest quartile of CRP levels had an atrial fibrillation
recurrence rate of 71%, whereas in those in the lowest
quartile the recurrence rate was 12%.
At variance with NT-proBNP levels, no differences were
observed in CRP levels measured before and after elec-
trical cardioversion either in patientswhomaintained sinus
rhythm (from 1.96mg/l, IQR: 0.6–3.0 to 1.90mg/l, IQR:
1.0–2.9; P¼ 0.31) or with relapsing arrhythmia (from
3.7mg/l, IQR:2.2–5.9 to3.35mg/l, IQR:1.6–7.1;P¼ 0.25).
CRP levels did not show significant correlations with any
parameter reflecting atrial dysfunction including LAD,
LAA, LAARV and NT-proBNP levels.
Predictive value of NT-proBNP and C-reactive protein
levels
In multinomial logistic regression analysis model
performed to identify predictors of atrial fibrillationorized reproduction of this article is prohibited.
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Fig. 4
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C-reactive protein (CRP) values before and 3 weeks after cardioversion
(CV) in patients with sinus rhythm (SR) maintenance and atrial
fibrillation (AF) recurrence. Horizontal line is set to cut-off value (3 mg/l).
Data are presented as median (interquartile range).
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Receiver operating characteristic (ROC) for C-reactive protein (CRP)
and arrhythmia recurrence. An optimal cut-off value of 3.6 mg/dl (similar
to upper quartile distribution value of 3.7 mg/l) minimizing false positive
and negative results was selected, obtaining positive and negative
predictive values of, respectively, 64 and 81%.recurrence, variables classically associated with arrhyth-
mia recurrence like age, LAD, LAA, LAAEV, NT-
proBNP level, history of previous atrial fibrillation,
arrhythmia duration or antiarrhythmic medication failed
to reach a statistical significance. On the contrary, CRP
levels were significantly associated with arrhythmia
recurrence with an OR of 1.6 (95% CI: 1.04–2.5;
P¼ 0.031). When considering the variable as dichotomic,
splitting CRP serum concentration obtained at T-0
analysis by the cut-off values of 3mg/l, a significant
difference in atrial fibrillation recurrence rate between
the two groups (P¼ 0.027) was observed. A CRP value
of at least 3.0mg/l presented a positive and negative
predictive value of, respectively, 58 and 78% for early
atrial fibrillation recurrence. The percentage of atrial
fibrillation recurrence was, respectively, 12, 25, 33 and
71% in the four quartiles of CRP distribution, ranging
from lower to higher values (P< 0.001; Fig. 5). By con-
structing a ROC curve for CRP and arrhythmia recur-
rence, we identified an optimal cut-off value of 3.6mg/dl
(similar to upper quartile distribution value of 3.7mg/l)
minimizing false positive and negative results (ROC area:
0.76), obtaining positive and negative predictive values
of, respectively, 64 and 81% (Fig. 6).
Discussion
The main results of this study were the following: in
patients with persistent atrial fibrillation and preserved
LVEF, none of the atrial parameters reflecting atrial
dysfunction or strain was associated with atrial fibrillationopyright © Italian Federation of Cardiology. Unaurecurrences; CRP levels measured before cardioversion
predicted arrhythmia recurrences and were not modified
by the underlying rhythm; NT-proBNP levels were
inversely correlated with LAAEV and significantly
decreased after recovery of sinus rhythm.
Atrial strain and atrial fibrillation
In the present study, LAD, LAA, LAAEV and NT-
proBNP levels were used as indices of atrial strain associ-
ated with the abnormal hemodynamic function thatthorized reproduction of this article is prohibited.
Cop
586 Journal of Cardiovascular Medicine 2008, Vol 9 No 6characterize atrial fibrillation patients [10]. In spite of a
normal or LVEF and in absence of any echocardio-
graphic evidence of left ventricular hypertrophy, a
left atrium enlargement was present in more than
70% of the patients and a reduced LAAEV was
measured in all subjects. NT-proBNP levels were elev-
ated in all but two patients. It is well known that B-type
natriuretic peptide is released in response to myocite
stretch by ventricular myocites [10] and is considered
the best accepted diagnostic tool in the evaluation of
dyspnea in the emergency department [11]. In asymp-
tomatic middle-aged persons, the level of B-type
natriuretic peptide is an independent predictor of
death, heart failure, atrial fibrillation and stroke in a
5-year follow-up [12].
In our study, carried out in a selected group of patients
with preserved LVEF and a history of hypertension in
more than 50% of cases, high levels of NT-proBNP were
likely to reflect factors related to atrial fibrillation rather
than a subclinical heart disease. It is possible that dias-
tolic dysfunction due to rhythm irregularity and loss of
atrial contribution to ventricular filling as well as the
increased atrial strain associated with atrial fibrillation
might have caused NT-proBNP level elevation. The
significant correlation between LAAEV andNT-proBNP
is consistent with this hypothesis and confirms the
sensitivity of this parameter to reflect the functional
severity of hemodynamic alterations associated with atrial
fibrillation. This interpretation is also supported by the
fact that after cardioversion, NT-proBNP levels signifi-
cantly decreased only in patients who maintained sinus
rhythm.
The reduction in NT-proBNP levels after successful
cardioversion observed in the present study is in agree-
ment with previous observation [13,14] that reported a
reduction in NT-proBNP levels after recovery of sinus
rhythm in patients with preserved LVEF and paroxysmal
or persistent atrial fibrillation. In both studies, NT-
proBNP levels were not related to arrhythmia duration
and were not correlated with atrial dimension. In our
study, in which we measured, in addition, LAAEV as an
indirect index of atrial mechanical dysfunction, a signifi-
cant inverse correlation between NT-proBNP levels and
LAAEV was instead observed. The consistent finding
that NT-proBNP levels were not increased by DC shock
but significantly decreased immediately after restoration
of sinus rhythm opens, in our opinion, new possibility
for the utilization of this parameter as a noninvasive
marker of arrhythmia burden in patients with either
asymptomatic or short-lasting episodes of atrial fibrilla-
tion. Detection of asymptomatic recurrences is a major
clinical problem: one could hypothesize that in patients
with a history of atrial fibrillation, the demonstration of
normal NT-proBNP levels could confirm the presence of
an arrhythmia free period.yright © Italian Federation of Cardiology. UnauthSubclinical inflammation and atrial fibrillation
The association between atrial fibrillation and inflam-
mation is supported by the frequent association between
inflammatory disease such as myocarditis or pericarditis
and atrial fibrillation [6,7]. The increased frequency of
atrial fibrillation after cardiac surgery [15] is commonly
interpreted as an indirect evidence for this pathophysio-
logical hypothesis [6,7]. Presence of inflammatory infil-
trates and oxidative damage has been demonstrated in
atrial biopsies of atrial fibrillation patients, thus providing
a histopathological evidence [16].
In the last decade, several studies [6,7,17], by using
markers of inflammation such as CRP and interleukin-6,
have indicated higher levels of both the parameters in
patients with atrial fibrillation than in controls in sinus
rhythm. Moreover, patients with persistent atrial fibril-
lation have been found to present higher CRP levels than
the patients with paroxysmal atrial fibrillation in relation
to a longer arrhythmia duration and atrial dimension, thus
suggesting a link between inflammation and structural
remodeling [5,6]. Regarding this latter factor, it is impor-
tant to recognize that angiotensin II has been identified
as a potential contributor to inflammation also in atrial
fibrillation patients [6,7,18]. Thus, inflammation may
represent one of the pathways by which the activation
of the renin–angiotensin–aldosterone system concurs to
the development and perpetuation of atrial fibrillation,
linking neuro-humoral alterations, structural remodeling
and susceptibility to atrial fibrillation [5–7].
In the present study, carried out in patients with preserved
LVEF, history of hypertension and ACE inhibitor treat-
ment in about two out of three cases, we observed higher
CRP levels in patients with atrial fibrillation recurrence,
thus confirming the predictive role of this marker of
subclinical inflammation also in patients with persistent
atrial fibrillation [19–22]. Moreover, we observed that
neither restoration of a more physiological hemodynamic
condition nor persistence of atrial fibrillation determined
any significant change in CRP levels during the 3-week
period of observation.
These findings are in agreement with previous reports
[19,21,22] that have indicated CRP as a predictor for
recurrence of atrial fibrillation after successful cardiover-
sion. In the above as well as in our study, CRP levels were
not correlated with atrial dimension, arrhythmia duration
or antiarrhythmic drug administration. Watanabe et al.
[20] reported, in addition, that CRP levels were also
predictors of successful cardioversion and found a sig-
nificant correlation between CRP levels and extent of
coronary artery disease, smoking, diabetes and atrial
fibrillation duration. In the same study, the authors
observed a reduction in CRP levels after cardioversion
only in patients with atrial fibrillation recurrences,
whereas CRP levels remained unchanged in thoseorized reproduction of this article is prohibited.
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follow-up period. It is our opinion that major differences
in the study population might explain these different
results: the lower success rate of cardioversion and
the higher atrial fibrillation recurrence rate reported in
Watanabe study support, in our opinion, this interpreta-
tion.
In conclusion, all these findings are consistent with the
concept that CRP levels might reflect the structural
changes associated with atrial fibrillation and that sub-
clinical inflammation is one of its most important com-
ponents. This interpretation is confirmed by the study of
Ellinor et al. [23], who analyzed CRP and interleukin-6
levels in lone and hypertensive atrial fibrillation patients.
These authors found higher values in the latter group
but at variance with our study did not observe any sig-
nificant correlation between CRP levels and atrial fibril-
lation recurrences. Recently [24], higher CRP levels have
been reported in patients with the first symptomatic
episode of paroxysmal atrial fibrillation and found asso-
ciated with atrial fibrillation recurrences as in our report
in patients with persistent atrial fibrillation.
The presence of high CRP levels in patients with atrial
fibrillation recurrences not only emphasizes the pro-
arrhythmic role of subclinical inflammation but also
opens new perspectives to consider CRP levels, which
have also been associated with stroke incidence [25], as a
therapeutical target. Preliminary results indicate that
pharmacological treatments such as those with ACE
inhibitors [26,27] and statins [6,28] may exert a beneficial
effect in atrial fibrillation patients by modulating those
factors that are known to affect structural remodeling and
have the inflammatory process as one of their major
components. In this context, the potential beneficial
effect of steroids and fish oil could also be considered.
Dernellis and Panaretou [29] reported that methyl-
prednisolone, an adjunct to amiodarone, significantly
reduced arrhythmia recurrence rate in patients with per-
sistent atrial fibrillation, whereas Calo` et al. [30] showed
that pretreatment with omega n-3 fatty acids reduced the
incidence of postcardiac surgery atrial fibrillation in com-
parison with patients treated conventionally.
All the above data seem, therefore, to support the concept
that pharmacological modulation of inflammatory mech-
anisms might be a potential beneficial strategy in atrial
fibrillation patients.
Study limitations
The small number of patients enrolled in the study is,
probably, its major limitation. The study, however, was
restricted to a homogeneous group of subjects without
evidence of organic cardiomyopathy, thus limiting the
confounding effects of factors such as left ventricular
dysfunction known to affect atrial parameters or NT-opyright © Italian Federation of Cardiology. UnauproBNP levels. A second limitation is the fact that the
study duration was limited to a 3-week period, which,
however, accounts for the greatest rate of recurrences after
cardioversion [4,5]. Subacute arrhythmia recurrence rate
was indeed consistent with previous reports [4,5] and an
adequate logistic regression analysis model was used to
evaluate the predictive value of CRP. Finally, it is import-
ant to recall that in this study, relapses identification was
based on symptoms in the first 2 weeks and on ECG
recordings at 3 weeks after cardioversion. This protocol
timing could have underestimated the real incidence of
atrial fibrillation recurrences by excluding asymptomatic
episodes of short duration, whose effects on NT-proBNP
and CRP values have not yet been determined.
Conclusions
The present study indicates that in patients with pre-
served LVEF and a history of hypertension, CRP levels
rather than indices of atrial dysfunction predict arrhyth-
mia recurrences. On the contrary, NT-proBNP levels,
which significantly decrease after sinus rhythm recovery,
appear to better reflect the hemodynamic alterations
secondary to arrhythmia presence. The possibility of
using NT-proBNP as a marker of atrial fibrillation burden
in atrial fibrillation patients is a hypothesis that deserves
further investigation.
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